Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022 Nov 3, 2022
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Oct 20, 2022
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem Sep 19, 2022
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep 7, 2022
